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Despite well over a century of research on all forms of the disorder known as Alzheimer’s disease 
(AD), it is still not known whether the condition targets initially neurons, glial cells, other cellular 
elements in the brain, or components of cells, such as synapses, or molecules independently 
of their cellular compartmentalization, or otherwise (e.g., specific neuronal circuits). Multiple 
lines of highly suggestive but as yet insufficient experimental evidence are discussed here 
to formulate the hypothesis that AD results from primary (i.e., direct and initial) or secondary 
targeting of what we designate as the Fourth Element Cell (4EC): a relatively recently identified 
type of brain cell that exhibits features in common with neurons (e.g., synapses, participation 
in glutamatergic, and GABAergic neurotransmission), astrocytes, oligodendrocytes, and their 
precursors, but is in other respects clearly distinct from all of them. The 4EC is proposed to be the 
main target of both: (1) converging insults (i.e., not true “causes”) that over time cause sporadic 
forms of AD as postulated by the Danger Signal Hypothesis – which was not formulated with 
4EC in mind – as well as (2) the causes of inherited (i.e., familial) forms of neurodegeneration 
that resemble certain aspects of the clinical manifestations of sporadic AD.
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from either single causes of the sADs (i.e., the very rare, so-called 
“familial AD” that shares some of the phenotypes of the sADs, and 
quite often has clinical manifestations that are atypical for sADs), or 
the proposed converging set of risk vs. protective factors that appear 
to be by far the most common precipitating events leading to AD 
(Fernández et al., 2008; Kuljiš, 2009a,b, 2010a,b). This is relevant 
to a current, unresolved debate as to whether the primarily tar-
geted element(s) in AD are neurons (Wirths et al., 2004; Bayer and 
Wirths, 2010), astrocytes (Selinfreund et al., 1991; Marshak et al., 
1992; Sheng et al., 1994; Morgan et al., 1997; Johnstone et al., 1999; 
Naegele et al., 2003; Wyss-Coray et al., 2003; Kashon et al., 2004; 
Pertusa et al., 2007; Simpson et al., 2010), or microglia (Rogers et al., 
2007; Fernández et al., 2008; Leung et al., 2009; Streit et al., 2009; 
Ager et al., 2010; Eikelenboom et al., 2010), and the overarching 
concern as to whether the postulated – and not mutually exclud-
ing – roles of nucleic acid damage (Gleckman et al., 1999; Myung 
et al., 2008), inflammation (Sastre et al., 2006; Rogers et al., 2007; 
Rojo et al., 2009; Eikelenboom et al., 2010; Heneka et al., 2010) and 
oxidative stress (Nunomura et al., 2006a,b; Myung et al., 2008) that 
are strongly felt to be central to the disease process target specific 
brain regions and circuits (Kuljiš, 2009b, 2010b), and/or cell types 
(as stated above, loc.cit.), and/or components of cells – such as syn-
apses (De Kosky and Scheff, 1990; Terry et al., 1991; Bell and Cuello, 
2006; Arendt, 2009) – rather than any of the former elements of the 
brain, or, instead, specific molecules regardless of which cellular 
and subcellular components or compartments they are situated in, 
even outside the brain. The recent finding that pancreatic lesions 
grossly resembling those in the brain occur in AD (Miklossy et al., 
2010) can in fact support the latter possibility, or, alternatively, when 
considering the similarities between neurons and pancreatic beta 
IntroductIon
The “sporadic” (i.e., non-familial) form of the Alzheimer’s disease 
(AD) syndrome (sADs, where the first “s” is for “sporadic,” and the 
second “s” is for “syndrome”) is by far the most common form of 
this disorder, and appears to result from a more or less individually 
unique set of converging risk factors, inadequately counterbalanced 
by a set of hypothetical protective factors that is also relatively 
unique to the individual affected (Fernández et al., 2008; Kuljiš, 
2009a, 2010b). Here we postulate that these sets of opposing factors 
operate over decades – primarily (i.e., pathogenically) or secondar-
ily (i.e., as a “common final pathway” of prior events) – to target the 
so-called “polydendrocytes,” a.k.a. beta astrocytes and the “fourth 
neuroglial type,” a relatively recently discovered (Reyners et al., 
1982, 1986) and subsequently confirmed type of neural cell (Peters, 
2004; Nishiyama et al., 2009; Bergles et al., 2010). We designate them 
here as the “Fourth Element” cell (4EC) following the tradition 
established by Santiago Ramón y Cajal when he made a distinc-
tion between neurons, macroglia, and all other types of cells in the 
brain, and lumped the latter types of cell into a “Third Element.” 
Pío del Río Hortega subsequently discovered – and named – what 
we know today as the microglia from among the Third Element, 
employing a battery of silver carbonate impregnation methods. 
Modern technology has confirmed del Río Hortega’s discoveries, 
and demonstrated that altered forms of microglia participate in the 
pathology of AD, since they are a key component of senile plaques 
(Peress et al., 1993; Rogers et al., 2007; Leung et al., 2009; Streit 
et al., 2009) and other lesions (Streit et al., 2009).
In the present formulation, we propose that virtually all forms of 
the AD syndrome (ADs) result from targeting of the 4EC, whether 
it is the primary (i.e., initial event) or a secondary insult resulting 
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to DNA damage and/or free radical toxicity, or both, since there 
are far more mitotically active than all other types of glial cells. 
These unusual properties were summarized by Peters (2004) in 
an elegant study of their ultrastructurally unique characteristics. 
4EC cells, which he dubbed the β neuroglial cells, have pale, irregu-
larly shaped nuclei with a thin rim of heterochromatin under the 
nucleolemma and a pale cytoplasm. These cells are common in the 
brain of rodents and non-human primates, including the cerebral 
neocortex and hippocampus known to be targeted in AD (Kuljiš, 
2009a,b, 2010b). In monkeys, there are at least two types of Peters’ 
β neuroglial cells (a.k.a. “NG2 cells”), one with a darker nucleus 
than the more abundant type containing a lighter nucleus (Peters, 
2004), suggesting that there may be various types of cell within the 
broad category of 4EC. While it is clear that the 4EC are neither 
conventional microglia nor oligodendrocytes, it is very easy to con-
fuse them with astrocytes due to their superficial resemblance to the 
latter (Reyners et al., 1982,1986). However, 4EC are said to differ 
from astrocytes not only in the absence of intermediate filaments 
characteristic of the latter, but, as mentioned, in that they have a 
more irregularly shaped nucleus, a more regularly shaped cell body 
than protoplasmic astrocytes, and their mitochondria are thinner 
that those in astrocytes. Furthermore, 4EC are separated from the 
basal lamina of cerebral microvessels by intervening processes of 
astrocytes (Peters, 2004).
It is not known whether or how 4EC are involved in neuro-
degenerative disorders, whether AD or other conditions, such as 
Multiple Sclerosis – which is intriguing due to their suspected role as 
precursors of oligodendrocytes among other cell lineages, including 
possibly even neurons (Nishiyama et al., 2009).
4Ec arE thE rEcIpIEnts of nEuron-glIa synapsEs
Perhaps the most intriguing feature about 4EC is that they are 
the cells first identified by Bergles et al. (2000) as a type of glia 
receiving glutamatergic input from hippocampal pyramidal cells 
(known to be targeted in AD) and by inhibitory interneurons 
(also targeted in AD). In fact, both in the gray and white matter, 
there is an NG2-expressing glial cell that express also ionotropic 
receptors for glutamate and GABA
A
 and have direct synaptic 
junctions with axons that enable the transient activation of these 
receptors. Furthermore, these exhibit all the features of “classical” 
neuron-to-neuron synapses including rapid activation, quantized 
responses, depression and facilitation and presynaptic inhibition 
(Nishiyama et al., 2009; Bergles et al., 2010). NG2-containing cells 
also express AMPA receptors, exhibit permeability to calcium, 
and express also NMDA receptors which raises the likelihood that 
they may be susceptible to excitotoxic injury. It is therefore highly 
plausible that this novel mechanism for neuron-glia signaling is 
important not only for the normal brain, but also relevant for the 
diseased central nervous system (Bergles et al., 2010) although, 
to the best of our knowledge, they have never been implicated 
in AD. This is undoubtedly due mainly to the lack of awareness 
of the existence of the 4EC. However, among other possibili-
ties, the targeting of 4EC we postulate may underlie the observed 
reduction in excitatory amino acid transporters that correlates 
with AD clinical manifestations, which has been attributed so far 
only to astrocyte damage, but not to 4EC degeneration (Simpson 
et al., 2010).
cells, the former cell-based explanations. This unresolved debate is 
thus central to the elucidation of the key mechanisms underlying 
AD, as well as to additional, urgent public health issues such as the 
controversy about the potentially common mechanisms underly-
ing the converging epidemics of diabetes and dementia worldwide 
(Kuljiš and Šalkovic´-Petrišic´, 2010).
The present hypothesis is based on: (1) the evidence for glial par-
ticipation in the pathophysiology of AD shown by Alzheimer (1906, 
1907), and confirmed repeatedly ever since (Perusini, 1910, 1911; 
Beach et al., 1989; Peress et al., 1993; Sheng et al., 1994; Simpson 
et al., 2010), since 4EC are considered by most as glial cells (loc.cit), 
(2) a revision of the Danger Signals Hypothesis of AD pathogenesis 
(Fernández et al., 2008) which, makes use of the massive convergent 
evidence for susceptibility and protective factors that appear to oper-
ate over decades to eventually produce AD, but that originally had 
no significant role for the increasingly apparent macroglial involve-
ment in this condition (summarized in the paragraph above, and 
discussed in more detail below), and (3) the experimentally unas-
serted involvement of the 4EC in AD, which is very likely because of 
their demonstrated hypersensitivity to DNA damage (Reyners et al., 
1982, 1986) which is know to occur in AD (Gleckman et al., 1999; 
Myung et al., 2008) but had not been linked yet to the involvement 
of 4EC hypothesized here. This is consistent with the fact that DNA 
damage has already been identified in closely related neurodegen-
erative disorders (Gleckman et al., 1999) making our hypothesis 
plausibile. Furthermore, addressing this possibility in AD – but not 
considering the potential involvement of 4EC often confused with 
astrocytes – Myung et al. (2008) speculated that “…While the exact 
effect of the astrocytic DNA damage on the functions and vitality of 
astrocytes is unclear, the presence of DNA damage alone may not 
signify apoptosis but more likely identifies a subset of vulnerable 
astrocytes in which mechanisms of both cell death and repair have 
been activated…” (the emphasis is ours). This obviously opens the 
possibility that at least part of the astrocyte-like population sus-
ceptible to DNA damage in AD are 4EC (i.e., those first recognized 
by Reyners et al., as described in the next subsection), rather than 
true astrocytes.
an ovErvIEw of thE dIscovEry and charactErIzatIon 
of 4Ec
In a set of two studies that have received surprisingly little atten-
tion, Reyners et al. (1982, 1986) described their discovery of a large 
population of “unconventional” cells, that they felt erroneously is 
a previously unidentified astrocyte, that differs from the classically 
defined neuroglia in that: (1) they are antigenically different from 
astrocytes, oligodendrocytes and microglial cells, (2) express NG2 
chondroitin sulfate proteoglycan-like immunoreactivity, (3) have 
no cytoplasmic intermediate filaments (e.g., GFAP, vimentin, and 
S100 protein), and exhibit a variety of ultra structural features 
different from astrocytes although they superficially resemble astro-
cytes (discussed below), (4) they cannot be labeled with markers for 
microglia, although they do express mRNA encoding proteolipid 
protein and myelin basic protein, (5) some of these cells appear to 
be oligodendrocyte progenitors and lose the NG2-like immunore-
activity as they mature, (6) they do not react with antibodies that 
recognize neurons, and (7) are more radiosensitive than conven-
tional glial cells, which we presume may reflect their susceptibility 
www.frontiersin.org November 2010 | Volume 1 | Article 144 | 3
Kuljiš Fourth element targeting Alzheimer’s disease
this hypothesis may lead to the implementation of assays for 4EC 
involvement by cerebrospinal fluid analysis, or blood-borne indi-
cators of 4EC involvement, or in vivo imaging assessment of such 
involvement (with ligands for 4EC) – or a combination of these – 
as well as a more refined histopathological assessment for patients 
with Mild Cognitive Impairment and dementia postmortem. The 
above considerations are relevant also to our recent assessment of 
the intersection of the epidemics of dementia and diabetes, since 
this is one additional situation in which the elucidation of the tar-
geted vs. spared or disease-resistant elements is essential to move 
beyond conflicting interpretations of the same or closely related 
experimental observations (Kuljiš and Šalkovic´-Petrišic´, 2010).
It has not escaped our attention that casting hypotheses on 
the primary targeting mechanisms causing AD in terms of one 
or another cell type – or cellular component, such as synapses – 
may be narrow-minded and ultimately inadequate. In fact, given 
the: (1) seemingly “unconventional” nature of 4EC, which share 
cytological and molecular features with neurons, macroglia, and 
oligodendrocytes, (2) the evidence that markers previously felt to 
be unique to neurons – such as doublecortin – or macroglia – such 
as S100B – are expressed by a variety of other cell types (Steiner 
et al., 2007; Verwer et al., 2007), and (3) that the S100B/RAGE-
mediated activation of microglia (Bianchi et al., 2010) indicates 
there may be and inextricable interaction between 4EC, macro- 
and microglia in the genesis of brain inflammation that initially 
triggers neurodegeneration (Fernández et al., 2008; Rojo et al., 
2009; Eikelenboom et al., 2010; Heneka et al., 2010), it may be 
difficult to discern between a primary/initial macro- vs. micro-
glial trigger of AD. This challenge is in fact compounded by the 
4EC hypothesis, since 4EC share properties with several neural cell 
types. However, it would seem that casting the present hypothesis 
in terms of a putative primary involvement of 4EC is scientifically 
testable, and provides a heuristically useful counterbalance to the 
presently massive – if appropriate – attention to the suspected role 
of microglia in the early mechanisms mediating AD (Fernández 
et al., 2008; Leung et al., 2009; Rojo et al., 2009; Streit et al., 2009; 
Ager et al., 2010). This will require further characterization of 4EC 
in both the normal and diseased human and non-human brain, 
to approach the level of sophistication with which it is possible 
to study today the involvement of more “conventional” types of 
cell in the brain and other organs. None of the above hypothetical 
scenarios are contradictory or incompatible with the eventual (i.e., 
secondary) dysfunction, followed by the degeneration and death of 
neurons, as the final mediator of the clinical manifestations of AD 
and related disorders as proposed by most prior authors, includ-
ing ourselves (Fernández et al., 2008; Kuljiš, 2009a,b, 2010b; Rojo 
et al., 2009; Kuljiš and Šalkovic´-Petrišic´, 2010). Such secondary 
events include also inflammation and the (intra- and extracellular) 
accumulation of pathological forms of amyloid and tau proteins, 
regardless of whether these are cast as disease-compounding, or 
ultimately ineffective or counterproductive attempts at cellular and 
molecular defense.
acknowlEdgmEnts
The author is grateful to Harvey J. Karten, M.D., both for criti-
cism of an early version of the manuscript, as well as for an earlier, 
seminal discussion in which he forced the author to  reassess 
cavEats on a cEllular-lEvEl formulatIon
Given the ongoing dramatic changes in the distinction between 
neurons and glial cells in the brain, the proposal that 4EC are piv-
otally involved in AD defies the former notion that the targeted 
element(s) can be conceptualized simplistically as neurons vs. mac-
roglia vs. microglia, vs. other cells that are not of a neural lineage. 
In fact, considering the still unresolved nature of 4EC as precursors 
or variants of oligodendrocytes, their near-neuronal attributes (e.g., 
synapses and the participation on glutamatergic and GABAergic 
neurotransmission) and their features in common with “con-
ventional” astrocytes, their postulated primary, even pathogenic, 
involvement in AD blurs the distinction among all conventional 
cell types in AD. Even if the present proposal about the predomi-
nant targeting of 4EC in AD does not survive experimental testing, 
it casts doubt on the ability to postulate targeting mechanisms 
based exclusively on neuronal vs. glial phenotypes. Thus, it is also 
possible that it is not specific cell types, but key attributes shared 
between neuronal and non-neuronal cells that are targeted early 
on in the disease process, if this process attacks first – or in any way 
selectively – neural cells.
ImplIcatIons of thE fourth ElEmEnt targEtIng 
hypothEsIs to conquErIng thE InnovatIon gap and 
translatIonal applIcatIons to thE prEvEntIon and 
trEatmEnt of ad
Progress in conquering AD and related disorders is hampered by 
the so-called Innovation Gap (IG), which is a collection of chal-
lenges that includes: (a) the fact that the number of approved 
treatments has not increased despite substantial increments in 
the investment toward the discovery and testing for this purpose 
over decades, (b) the frequent lack of predictive power for the 
efficacy in humans of the outcomes of testing in so-called “models” 
of the disorder, and (c) the failure of all trials published to date 
based on the overwhelmingly dominant amyloid hypothesis of AD 
pathogenesis (Kuljiš, 2009b, 2010a). If the 4EC hypothesis is cor-
rect, it would open an essentially unexplored avenue for research 
and treatment development that could have a powerful effect in 
overcoming the IG.
A recent report provides powerful evidence that it may now pos-
sible to predict the outcome of patients at risk of developing AD, by 
measuring putative markers of the disorder that include β-amyloid 
and both total and phosphorylated tau protein in the cerebrospinal 
fluid (De Meyer et al., 2010). However, markers with proven diag-
nostic value do not presently include indicators of inflammation, 
macroglial alterations, and, much less, 4EC involvement, although 
there are numerous reports suggesting – but not  proving – that the 
former may also be of diagnostic value (Crols et al., 1986; Wallin 
et al., 1996; Fukuyama et al., 2001; Peskind et al., 2001; Petzold et al., 
2003). Given the probable multifactorial nature of sADs (Fernández 
et al., 2008), it is likely that an array of markers addressing different 
mechanisms involved in the condition may help to: (1) increase 
the sensitivity and specificity of the tests under development, (2) 
discern subtypes of patients in which different mechanisms mediate 
cognitive impairment, and (3) predict and monitor the response 
to various alternative mechanism-selective treatments. Therefore, 
whether the hypothetical 4EC mechanism proposed here is univer-
sal, or unique to certain groups of patients, research aimed at testing 
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